^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Small Cell Lung Cancer |
| Drug: | Imfinzi (durvalumab) (PD-L1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Imfinzi approved in China for the treatment of extensive-stage small cell lung cancer
Published date:
07/19/2021
Excerpt:
AstraZeneca’s Imfinzi (durvalumab) has been approved in China for the 1st-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC), in combination with standard of care platinum chemotherapy (etoposide plus a choice of either carboplatin or cisplatin).
Secondary therapy:
carboplatin + etoposide IV; cisplatin + etoposide IV
Source:
Title:
Imfinzi approved in the EU for the treatment of extensive-stage small cell lung cancer
Published date:
09/01/2020
Excerpt:
AstraZeneca’s Imfinzi (durvalumab) has been approved in the European Union for the 1st-line treatment of adults with extensive-stage small cell lung cancer (ES-SCLC) in combination with a choice of chemotherapies, etoposide plus either carboplatin or cisplatin.
Secondary therapy:
carboplatin + etoposide oral; cisplatin + etoposide oral
Source:
Title:
Imfinzi approved in Japan for the treatment of extensive-stage small cell lung cancer
Published date:
08/21/2020
Excerpt:
AstraZeneca’s Imfinzi (durvalumab) has been approved in Japan for the treatment of patients with extensive-stage small cell lung cancer (ES-SCLC), in combination with etoposide plus a choice of platinum chemotherapy (either carboplatin or cisplatin). SCLC is a highly aggressive, fast-growing form of lung cancer that typically recurs and progresses rapidly, despite initial response to chemotherapy.
Secondary therapy:
carboplatin + etoposide oral; cisplatin + etoposide oral
Source:
Excerpt:
IMFINZI is a programmed death-ligand 1 (PD-L1) blocking antibody indicated:...in combination with etoposide and either carboplatin or cisplatin, as first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).
Secondary therapy:
carboplatin + etoposide oral; cisplatin + etoposide oral
Source:
Title:
Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Published date:
04/14/2021
Excerpt:
Recommendations: An anti-PD-L1 inhibitor (atezolizumab [I, A; ESMO-MCBS v1.1 score: 3] or durvalumab [I, A; ESMO-MCBS v1.1 score: 3]) in combination with four to six cycles of a platinum and etoposide can be offered to all patients with treatment-naive extensive-stage SCLC, a PS of 0-1 and no contraindications for immunotherapy [I, A].
Secondary therapy:
etoposide IV
DOI:
10.1016/j.annonc.2021.03.207
Source:
Excerpt:
Small Cell Lung Cancer: Preferred regimen...Cisplatin...and etoposide...and durvalumab...Carboplatin...and etoposide...and durvalumab...
Secondary therapy:
cisplatin + etoposide oral; carboplatin + etoposide oral
Source:
Title:
P48.03 - First-Line Durvalumab plus Platinum-Etoposide in ES-SCLC: Exploratory Analyses Based on Extent of Disease in CASPIAN
Published date:
01/12/2021
Excerpt:
Treatment-naive patients (WHO performance status 0/1) with ES-SCLC received 4 cycles of durvalumab 1500 mg + EP q3w followed by maintenance durvalumab….Durvalumab + EP improved OS vs EP regardless of the extent of disease (thoracic-only HR 0.73 [95% CI 0.51–1.06]; extra-thoracic HR 0.77 [0.62–0.96]); PFS was also improved with durvalumab + EP vs EP in these subgroups (HR 0.70 [95% CI 0.49–1.00] and 0.85 [0.68–1.05], respectively)...OS and PFS were improved with durvalumab + EP...
Secondary therapy:
EP
Trial ID:
Source:
Title:
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
Published date:
12/04/2020
Excerpt:
Durvalumab plus platinum–etoposide showed sustained improvement in overall survival versus platinum–etoposide (HR 0·75 [95% CI 0·62–0·91]; nominal p=0·0032); median overall survival was 12·9 months (95% CI 11·3–14·7) versus 10·5 months (9·3–11·2)....durvalumab plus platinum–etoposide as a new standard of care for the first-line treatment of ES-SCLC.
Secondary therapy:
etoposide oral
DOI:
10.1016/S1470-2045(20)30539-8
Trial ID:
Source:
Title:
Imfinzi showed a sustained overall survival benefit in 1st-line extensive-stage small cell lung cancer in the Phase III CASPIAN trial
Published date:
05/29/2020
Excerpt:
...Phase III CASPIAN trial showed AstraZeneca’s Imfinzi (durvalumab) in combination with a choice of chemotherapies, etoposide plus either carboplatin or cisplatin, demonstrated a sustained, clinically meaningful overall survival (OS) benefit for adults with extensive-stage small cell lung cancer (ES-SCLC) treated in the 1st-line setting.
Secondary therapy:
cisplatin + etoposide oral; carboplatin + etoposide oral
Trial ID:
Source:
Title:
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
Published date:
11/23/2019
Excerpt:
Durvalumab plus platinum-etoposide was associated with a significant improvement in overall survival, with a hazard ratio of 0·73 (95% CI 0·59-0·91; p=0·0047]); median overall survival was 13·0 months (95% CI 11·5-14·8) in the durvalumab plus platinum-etoposide group versus 10·3 months (9·3-11·2) in the platinum-etoposide group, with 34% (26·9-41·0) versus 25% (18·4-31·6) of patients alive at 18 months...First-line durvalumab plus platinum-etoposide significantly improved overall survival in patients with ES-SCLC...
Secondary therapy:
Platinum alkylating agent + etoposide oral
DOI:
10.1016/S0140-6736(19)32222-6
Trial ID:
